@article {10474, title = {Cubosomes for in vivo fluorescence lifetime imaging.}, journal = {Nanotechnology}, volume = {28}, year = {2017}, month = {2017 Feb 03}, pages = {055102}, abstract = {

Herein we provided the first proof of principle for in vivo fluorescence optical imaging application using monoolein-based cubosomes in a healthy mouse animal model. This formulation, administered at a non-cytotoxic concentration, was capable of providing both exogenous contrast for NIR fluorescence imaging with very high efficiency and chemospecific information upon lifetime analysis. Time-resolved measurements of fluorescence after the intravenous injection of cubosomes revealed that the dye rapidly accumulated mainly in the liver, while lifetimes profiles obtained in vivo allowed for discriminating between free dye or dye embedded within the cubosome nanostructure after injection.

}, keywords = {Animals, Carbocyanines, Cell Survival, Drug Compounding, Erythrocytes, Female, Fluorescent Dyes, Glycerides, Humans, Injections, Intravenous, Liposomes, Liver, Mice, Mice, Inbred BALB C, Nanoparticles, NIH 3T3 Cells, Optical Imaging, Particle Size, Spectroscopy, Near-Infrared, Time-Lapse Imaging}, issn = {1361-6528}, doi = {10.1088/1361-6528/28/5/055102}, author = {Biffi, Stefania and Andolfi, Laura and Caltagirone, Claudia and Garrovo, Chiara and Falchi, Angela M and Lippolis, Vito and Lorenzon, Andrea and Macor, Paolo and Meli, Valeria and Monduzzi, Maura and Obiols-Rabasa, Marc and Petrizza, Luca and Prodi, Luca and Rosa, Antonella and Schmidt, Judith and Talmon, Yeshayahu and Murgia, Sergio} } @article {7725, title = {Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.}, journal = {Int J Nanomedicine}, volume = {10}, year = {2015}, month = {2015}, pages = {4099-109}, abstract = {

The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conflicting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs{\textquoteright} binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients{\textquoteright} cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs{\textquoteright} functionalization by an anti-CD20 antibody improves tumor pharmacokinetic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies.

}, issn = {1178-2013}, doi = {10.2147/IJN.S78995}, author = {Capolla, Sara and Garrovo, Chiara and Zorzet, Sonia and Lorenzon, Andrea and Rampazzo, Enrico and Spretz, Ruben and Pozzato, Gabriele and N{\'u}{\~n}ez, Luis and Tripodo, Claudio and Macor, Paolo and Biffi, Stefania} } @article {3559, title = {A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome.}, journal = {Blood}, volume = {123}, year = {2014}, month = {2014 May 29}, pages = {3478-87}, abstract = {

A single-chain fragment variable (scFv) recognizing β2-glycoprotein 1 (β2GPI) from humans and other species was isolated from a human phage display library and engineered to contain an IgG1 hinge-CH2-CH3 domain. The scFv-Fc directed against β2GPI domain I-induced thrombosis and fetal loss, thus mimicking the effect of antibodies from patients with antiphospholipid syndrome (APS). Complement is involved in the biological effect of anti-β2GPI scFv-Fc, as demonstrated by its ability to promote in vitro and in vivo complement deposition and the failure to induce vascular thrombosis in C6-deficient rats and fetal loss in C5-depleted mice. A critical role for complement was also supported by the inability of the CH2-deleted scFv-Fc to cause vessel occlusion and pregnancy failure. This antibody prevented the pathological effects of anti-β2GPI antibodies from APS patients and displaced β2GPI-bound patient antibodies. The CH2-deleted antibody represents an innovative approach potentially useful to treat APS patients refractory to standard therapy.

}, keywords = {Abortion, Spontaneous, Animals, Antibodies, Monoclonal, Antiphospholipid Syndrome, Autoantigens, beta 2-Glycoprotein I, Complement Activation, Complement System Proteins, Human Umbilical Vein Endothelial Cells, Humans, Immunoglobulin G, Male, Mice, Protein Binding, Rats, Recombinant Proteins, Single-Chain Antibodies, Thrombosis, Trophoblasts}, issn = {1528-0020}, doi = {10.1182/blood-2013-11-537704}, author = {Agostinis, Chiara and Durigutto, Paolo and Sblattero, Daniele and Borghi, Maria O and Grossi, Claudia and Guida, Filomena and Bulla, Roberta and Macor, Paolo and Pregnolato, Francesca and Meroni, Pier Luigi and Tedesco, Francesco} }